Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals (AGIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,183,190
  • Shares Outstanding, K 69,260
  • Annual Sales, $ 117,910 K
  • Annual Income, $ -411,470 K
  • 60-Month Beta 1.80
  • Price/Sales 15.98
  • Price/Cash Flow N/A
  • Price/Book 6.58
Trade AGIO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -1.41
  • Number of Estimates 5
  • High Estimate -1.24
  • Low Estimate -1.67
  • Prior Year -1.60
  • Growth Rate Est. (year over year) +11.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.15 +16.04%
on 12/23/20
48.40 -1.34%
on 01/12/21
+5.13 (+12.04%)
since 12/21/20
3-Month
32.47 +47.06%
on 12/17/20
49.98 -4.46%
on 12/01/20
+12.36 (+34.93%)
since 10/21/20
52-Week
27.77 +71.92%
on 03/18/20
56.74 -15.85%
on 07/02/20
-6.05 (-11.25%)
since 01/21/20

Most Recent Stories

More News
Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO(R) (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today reported a full analysis of the final data, including mature...

AGIO : 47.75 (+3.89%)
Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation

- Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency in the U.S. in Q2 2021 and in the EU in Mid-2021 -

AGIO : 47.75 (+3.89%)
Agios to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that the company is scheduled to present at the...

JPM : 134.83 (-0.84%)
AGIO : 47.75 (+3.89%)
Are Options Traders Betting on a Big Move in Agios (AGIO) Stock?

Investors need to pay close attention to Agios (AGIO) stock based on the movements in the options market lately.

AGIO : 47.75 (+3.89%)
Agios (AGIO) to Sell Oncology Drugs to Servier for $2B, Stock Up

Agios (AGIO) sells its oncology business unit to French company Servier for around $2 billion. The company plans to solely focus on developing treatments for genetically defined diseases. Shares rise.

OMI : 25.95 (-4.49%)
BIO : 589.19 (-1.93%)
LMAT : 44.77 (-0.31%)
AGIO : 47.75 (+3.89%)
Thinking about buying stock in Agios Pharmaceuticals, Clovis Oncology, Aqua Metals, Cocrystal Pharma, or Luminar Technologies?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGIO, CLVS, AQMS, COCP, and LAZR.

AGIO : 47.75 (+3.89%)
CLVS : 6.38 (-2.67%)
COCP : 2.21 (-5.96%)
LAZR : 32.85 (+1.48%)
AQMS : 4.62 (+4.29%)
Servier to Acquire Agios Pharmaceuticals' Oncology Business

and , /PRNewswire/ -- Servier, a global pharmaceutical company, today announced that it has entered into an agreement for the acquisition of Agios Pharmaceuticals' oncology business including its commercial,...

AGIO : 47.75 (+3.89%)
Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties

- Agios to Dedicate All Resources to Advancing Mitapivat as a Potential Treatment for Three Initial Hemolytic Anemias and Building on its Scientific Expertise in Cellular Metabolism and PK Activation to...

AGIO : 47.75 (+3.89%)
Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease

- Treatment with Mitapivat Induced Hemoglobin Increase of greater-than or equal to1.0 g/dL in 6 of 11 (55%) Efficacy Evaluable Patients, Decreased Markers of Hemolysis, Reduced 2,3-DPG and Increased ATP...

AGIO : 47.75 (+3.89%)
Agios Pharmaceut Has Returned 19.5% Since SmarTrend Recommendation (AGIO)

SmarTrend identified an Uptrend for Agios Pharmaceut (NASDAQ:AGIO) on October 22nd, 2020 at $37.84. In approximately 1 month, Agios Pharmaceut has returned 19.49% as of today's recent price of $45.21....

AGIO : 47.75 (+3.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. It discovers and develops therapeutics in the field of cancer metabolism and inborn errors of metabolism. The Company's products include AG-221, AG-120, enzyme glutaminase and AG-348. Agios Pharmaceuticals, Inc. is based in Cambridge, Massachusetts....

See More

Key Turning Points

3rd Resistance Point 52.11
2nd Resistance Point 50.05
1st Resistance Point 48.90
Last Price 47.75
1st Support Level 45.69
2nd Support Level 43.63
3rd Support Level 42.48

See More

52-Week High 56.74
Last Price 47.75
Fibonacci 61.8% 45.68
Fibonacci 50% 42.26
Fibonacci 38.2% 38.84
52-Week Low 27.77

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar